Literature DB >> 7677333

I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling.

P Ernsberger1, M E Graves, L M Graff, N Zakieh, P Nguyen, L A Collins, K L Westbrooks, G G Johnson.   

Abstract

Data were presented showing that I1-imidazoline sites show a unique ligand specificity that differs markedly from that of any of the alpha 2-adrenergic subtypes or the I2-imidazoline sites labeled by [3H]idazoxan. On the other hand, the ligand specificity of I1-imidazoline sites is maintained across mammalian species (cow, rat, dog, and human) and between different tissues and cell types. I1-Imidazoline sites can be further distinguished from I2 sites because the latter, unlike I1 sites, were not present in RVLM membranes from bovine brain stem. Furthermore, I1-imidazoline sites were modulated by guanine nucleotides with a specificity appropriate for a receptor coupled to G-protein and were mainly localized to plasma membranes. I1-Imidazoline sites show a unique pattern of distribution between diverse tissues and cell types and appear to be a neuroepithelial marker as well as being present in secretory cells of the pancreatic islets. The widespread distribution of I1-imidazoline sites implies that the functional significance of this putative receptor may have been underestimated. The signaling pathway associated with the I1-imidazoline receptor remains to be fully elucidated, but is likely that activation of phospholipase A2 leading to release of arachidonic acid and subsequent generation of prostaglandins plays a major role.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7677333     DOI: 10.1111/j.1749-6632.1995.tb32388.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  29 in total

Review 1.  Biological significance of agmatine, an endogenous ligand at imidazoline binding sites.

Authors:  W Raasch; U Schäfer; J Chun; P Dominiak
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 2.  Centrally acting antihypertensive drugs: re-emergence of sympathetic inhibition in the treatment of hypertension.

Authors:  C R Benedict
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

Review 3.  Drugs acting on imidazoline receptors: a review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection.

Authors:  P Bousquet; J Feldman
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 4.  The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.

Authors:  P Ernsberger; J E Friedman; R J Koletsky
Journal:  J Hypertens Suppl       Date:  1997-01

5.  Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor.

Authors:  Po-Sheng Yang; Hung-Tsung Wu; Hsien-Hui Chung; Chun-Ta Chen; Chin-Wen Chi; Ching-Hua Yeh; Juei-Tang Cheng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-25       Impact factor: 3.000

6.  Inhibition of 5-HT3 receptor function by imidazolines in mouse neuroblastoma cells: potential involvement of sigma 2 binding sites.

Authors:  G J Molderings; K Schmidt; H Bönisch; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

7.  Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice.

Authors:  Q M Zhu; J D Lesnick; J R Jasper; S J MacLennan; M P Dillon; R M Eglen; D R Blue
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

8.  The function of alpha-2-adrenoceptors in the rat locus coeruleus is preserved in the chronic constriction injury model of neuropathic pain.

Authors:  Cristina Alba-Delgado; Gisela Borges; Pilar Sánchez-Blázquez; Jorge E Ortega; Igor Horrillo; Juan A Mico; J Javier Meana; Fani Neto; Esther Berrocoso
Journal:  Psychopharmacology (Berl)       Date:  2011-10-29       Impact factor: 4.530

9.  Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent.

Authors:  P Ernsberger; R J Koletsky; L A Collins; D Bedol
Journal:  Cardiovasc Drugs Ther       Date:  1996-06       Impact factor: 3.727

10.  Generation and characterization of novel human IRAS monoclonal antibodies.

Authors:  Bo Wang; Ying Liu; Yajun Shan; Zhenyu Yao; Xiaolan Liu; Ruibin Su; Qihong Sun; Yuwen Cong; Jin Li
Journal:  J Biomed Biotechnol       Date:  2009-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.